Advertisement

Journal of Endocrinological Investigation

, Volume 19, Issue 1, pp 54–58 | Cite as

Significant reversal of thyrotoxicosis-associated dilated cardiomyopathy with induction of the euthyroid state

  • Bruce E. Wilson
  • E. C. Hamilton
Case Report

Abstract

Thyrotoxicosis rarely precipitates heart failure. Older patients and those with underlying cardiac disease are at greater risk of experiencing this complication of thyrotoxicosis. A 43 year old male who presented with subclinical thyrotoxicosis, atrial fibrillation, and a dilated cardiomyopathy is discussed. There was no evidence of clinically significant underlying cardiac disease. At admission, the patient had an ejection fraction of 25%. Thyrotoxicosis was treated with propylthiouracil. At 14 weeks after hospitalization, the patient had an ejection fraction of 50% with significant reduction in cardiac chamber sizes and left ventricular mass index. He was biochemically euthyroid at that time. After ten months of propylthiouracil therapy, he had progressive improvement in cardiac function and decrease in left ventricular mass index. Thyrotoxicosis-associated cardiomyopathy may reverse significantly with treatment of thyrotoxicosis alone; this complication of thyrotoxicosis should be considered in any young individual with a dilated cardiomyopathy of unknown etiology.

Key-words

Thyrotoxicosis cardiomyopathy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Amidi M., Leon D.F., deGroot J., Kroetz F.W., Leonard J.J. Effect of the thyroid state on the myocardial contractility and ventricular ejection rate in man. Circulation 38: 229, 1968.PubMedCrossRefGoogle Scholar
  2. 2.
    Sandler G., Wilson G.M. The nature and prognosis of heart disease in thyrotoxicosis: a review of 150 patients treated with 131I. Q. J. Med. 28: 347, 1959.PubMedGoogle Scholar
  3. 3.
    Symons C., Richardson P.J., Feizi O. Hypertrophic cardiomyopathy and hyperthyroidism: a report of three cases. Thora 29: 713, 1974.CrossRefGoogle Scholar
  4. 4.
    Forfar J.C., Muir A.L., Sawers S.A., Toft A.D. Abnormal left ventricular function in hyperthyroidism: evidence for a possible reversible cardiomyopathy. N. Engl. J. Med. 307: 1165, 1982.PubMedCrossRefGoogle Scholar
  5. 5.
    Magner J.A., Clark W., Allenby P. Congestive heart failure and sudden death in a young woman with thyrotoxicosis. West. J. Med. 149: 86, 1988.PubMedCentralPubMedGoogle Scholar
  6. 6.
    Ikram H. The nature and prognosis of thyrotoxic heart disease. Q. J. Med. 54: 19, 1985.PubMedGoogle Scholar
  7. 7.
    Izumo S., Nadal-Ginard B., Mahdavi V. All members of the MHC multigene family respond to thyroid hormone in a highly tissue-specific fashion. Science 231: 597, 1986.PubMedCrossRefGoogle Scholar
  8. 8.
    Dillmann W.H. The cardiovascular system in thyrotoxicosis. In: Braverman L.E., Utiger R.D., (Eds.), Werner and Ingbar’s The Thyroid, ed. 6. Lippincott, Philadelphia, 1991, p. 759.Google Scholar
  9. 9.
    Cavallo A., Joseph C., Casta A. Cardiac complications in juvenile hyperthyroidism. Am. J. Dis. Child. 138: 479, 1984.PubMedGoogle Scholar
  10. 10.
    Wilson B.E., Newmark S.R. Thyrotoxicosis-induced congestive heart failure in an urban hospital. Am. J. Med. Sci. 308: 344, 1994.PubMedCrossRefGoogle Scholar
  11. 11.
    Biondi B., Fazio S., Carella C., Amato G., Cittadini A., Lupoli G., Saccè L., Bellastella A., Lombardi G. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J. Clin. Endocrinol. Metab. 77: 334, 1993.PubMedGoogle Scholar
  12. 12.
    Biondi B., Fazio S., Carella C., Sabatini D., Amato G., Cittadini A., Bellastella A., Lombardi G., Saccè L. Control of adrenergic overactivity by ß-blockade improves the quality of life in patients receiving long-term suppressive therapy with levothyroxine. J. Clin. Endocrinol. Metab. 78: 1028, 1994.PubMedGoogle Scholar
  13. 13.
    Ladenson P.W., Sherman S.I., Baughman K.I., Ray P.E., Feldman A.M. Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc. Natl. Acad. Sci. (USA) 89: 5251, 1992.CrossRefGoogle Scholar
  14. 14.
    Wilson B.E., Hobbs W.N. Pseudoephedrine-associated thyroid storm: thyroid hormone-catecholamine interactions. Am. J. Med. Sci. 306: 317, 1993.PubMedCrossRefGoogle Scholar
  15. 15.
    Woeber K.A. Thyrotoxicosis and the heart. N. Engl. J. Med. 327: 94, 1992.PubMedCrossRefGoogle Scholar
  16. 16.
    Liggett S.B., Shah S.D., Cryer P.E. Increased fat and skeletal muscle beta-adrenergic receptors but unaltered metabolic and hemodynamic sensitivity to epinephrine in vivo in experimental human thyrotoxicosis. J. Clin. Invest. 83: 803, 1989.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    MacMahon S.W., Wilcken D.E.L., MacDonald G.J. The effect of weight reduction on left ventricular mass. N. Engl. J. Med. 314: 334, 1986.PubMedCrossRefGoogle Scholar
  18. 18.
    Wynne J., Braunwald E. The cardiomyopathies and myocarditides: toxic, chemical and physical damage to the heart. In: Braunwald E. (Ed.), Heart disease: A textbook of cardiovascular medicine. W.B. Saunders, Philadelphia. 1992, p. 1394.Google Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1996

Authors and Affiliations

  • Bruce E. Wilson
    • 1
  • E. C. Hamilton
    • 1
  1. 1.Division of EndocrinologyUniversity of Nevada School of MedicineLas VegasUSA

Personalised recommendations